Compare Devon Energy Corp (DVN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Novartis AG — how do they compare? Devon Energy Corp trades at $45.45 (market cap $49.90B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 6× Devon Energy Corp's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| DVN | NVS | |
|---|---|---|
Market Cap | $49.90B | $298.18B |
Sector | Energy | Health |
52-Week High | $52.07 | $168.62 |
52-Week Low | $31.74 | $119.31 |
Enterprise Value | $60.63B | $339.50B |
Dividend Yield | 2.82% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $42.98, down 0.3% with a bearish technical signal. The company reported strong Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising its dividend 33% and accelerating debt reduction. Valuation metrics appear attractive with P/E of 9.34 and EV/EBITDA of 6.59, though net income margins have declined from 31.4% in 2022 to 15.4% in 2025.
The outlook remains positive with 71% analyst buy ratings and a $61.91 consensus price target representing 44% upside. Key catalysts include merger synergies from Coterra integration and strong free cash flow generation supporting shareholder returns. Risks include oil price volatility and execution of the $1B+ synergy target by 2027.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
